Macrophage–Adipoq+ Axis Drives Fibrosis in Osteomyelitis Abs
2026-06-28
Macrophage–Adipoq+ Axis Drives Fibrosis in Osteomyelitis Abscesses
Study Background and Research Question
Osteomyelitis, a severe bone infection most commonly caused by Staphylococcus aureus, remains a significant challenge in orthopedic medicine. Despite advances in surgical care and antibiotic therapy, posttraumatic bone infections persist—especially after open or complex fractures, with infection rates ranging from 2.2% in minor cases to as high as 59% in severe (grade III) injuries, particularly among vulnerable populations such as the elderly and diabetics. Chronic osteomyelitis is characterized by persistent abscess formation within the bone marrow, contributing to high recurrence rates and poor antibiotic penetration. While the cellular composition of these abscesses has been described, the mechanisms by which abscesses promote bacterial persistence and therapeutic failure have remained unclear. The reference study (Yang et al., 2025) aims to decipher the cellular and molecular drivers of abscess-associated fibrosis and vascular compromise in osteomyelitis.Key Innovation from the Reference Study
The pivotal innovation of the study lies in the identification of a direct regulatory axis between bone marrow macrophages and adiponectin-positive (Adipoq+) adipogenic lineage precursors. The authors demonstrate that amphiregulin (AREG), secreted by macrophages in the vicinity of S. aureus abscesses, activates the EGFR/mTOR/YAP pathway in Adipoq+ cells. This signaling cascade induces these precursors to transition into myofibroblasts—cells associated with fibrosis and vascular constriction. The resultant pathological remodeling restricts blood flow, impedes antibiotic delivery, and ultimately supports bacterial persistence within the bone. Notably, the study shows that targeted genetic or pharmacological disruption of this axis can reverse these effects, offering a new therapeutic avenue.Methods and Experimental Design Insights
The authors utilized a combination of murine models of implant-associated S. aureus osteomyelitis and advanced molecular-genetic tools. Blood perfusion in infected bone was assessed using Cdh5CretdTomato reporter mice, allowing real-time visualization of vascular changes. Cell lineage tracing and conditional knockout strategies enabled the selective ablation of Adipoq+ cells, as well as specific disruption of AREG in macrophages and EGFR in Adipoq+ precursors. To probe the functional consequences of pathway inhibition, both genetic deletions and pharmacological blockade of EGFR and mTOR were employed. Fibrosis, vascular perfusion, and bacterial burden were quantified through histological, functional, and microbiological assays. Together, these approaches provided a rigorous experimental platform to map cause-effect relationships at the cellular and signaling levels.Protocol Parameters
- Murine osteomyelitis model: Induce with implant-associated S. aureus infection; monitor abscess formation and perfusion using Cdh5CretdTomato mice.
- Cell type–specific genetic deletion: Use Adipoq-Cre or LysM-Cre drivers for conditional targeting of EGFR or AREG, respectively.
- Pharmacological inhibition: Administer EGFR or mTOR inhibitors at established effective dosages in vivo, following infection and during fibrotic response phases.
- Fibrosis and perfusion assessment: Employ immunostaining for myofibroblast markers (e.g., α-SMA) and vascular tracers to quantify local fibrosis and blood flow.
- Bacterial quantification: Plate bone marrow homogenates for colony-forming units (CFU) to assess antibiotic efficacy post-intervention.
Core Findings and Why They Matter
The study establishes that Adipoq+ adipogenic lineage cells are actively recruited to the periphery of S. aureus abscesses within bone marrow. There, under the influence of macrophage-derived AREG, these cells undergo a phenotypic switch to myofibroblasts, as confirmed by upregulation of myofibroblast markers and transcriptomic profiling. The resultant myofibroblast-rich zones induce vascular constriction, which was visualized as a marked reduction in local blood perfusion. This microenvironmental alteration directly impairs antibiotic delivery to the infection site, as evidenced by both functional imaging and diminished bacterial clearance despite systemic antibiotic treatment. Importantly, interventions disrupting the AREG/EGFR/mTOR/YAP pathway—either genetically or pharmacologically—led to decreased fibrosis, restored perfusion, improved antibiotic penetration, and reduced bacterial burden. These findings mechanistically link abscess-associated fibrosis to therapeutic failure and identify the macrophage–Adipoq+ axis as a modifiable determinant of infection persistence (Yang et al., 2025).Comparison with Existing Internal Articles
Several internal resources have addressed NF-κB signaling, inflammation, and infection models, often using small-molecule inhibitors such as QNZ (EVP4593):- "QNZ (EVP4593): Advanced Insights into NF-κB Inhibition and Fibrosis" discusses how potent NF-κB inhibitors can modulate inflammation-driven fibrosis, suggesting utility in infection and wound-healing models. While the reference study focuses on the AREG/EGFR/mTOR/YAP axis rather than NF-κB, both lines of research converge on the need for precise modulation of inflammatory and fibrogenic pathways to enhance infection outcomes.
- "QNZ (EVP4593): Potent NF-κB Inhibitor for Inflammation and Disease Models" emphasizes the role of NF-κB in inflammatory signaling and highlights QNZ's application in diverse disease models, including neurodegeneration and chronic inflammation. The present study complements these perspectives by dissecting a parallel but distinct axis of fibrosis in the context of bone infection.